Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study.
Ong KL, O'Connell R, Januszewski AS, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Scott RS, Taskinen MR, Waldman B, Colman PG, Best JD, Simes JR, Rye KA, Keech AC; FIELD study investigators. Ong KL, et al. Among authors: waldman b. Clin Chem. 2017 Jul;63(7):1261-1270. doi: 10.1373/clinchem.2016.270876. Epub 2017 Jun 12. Clin Chem. 2017. PMID: 28606915
Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study.
Waldman B, Ansquer JC, Sullivan DR, Jenkins AJ, McGill N, Buizen L, Davis TME, Best JD, Li L, Feher MD, Foucher C, Kesaniemi YA, Flack J, d'Emden MC, Scott RS, Hedley J, Gebski V, Keech AC; FIELD investigators. Waldman B, et al. Lancet Diabetes Endocrinol. 2018 Apr;6(4):310-318. doi: 10.1016/S2213-8587(18)30029-9. Epub 2018 Feb 26. Lancet Diabetes Endocrinol. 2018. PMID: 29496472 Clinical Trial.
Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study.
Cao JY, Waldman B, O'Connell R, Sullivan DR, Scott RS, Aryal N, Gebski V, Marschner I, Taskinen MR, Simes JR, McGill N, Jenkins AJ, Keech AC; FIELD investigators. Cao JY, et al. Among authors: waldman b. Diabetes Obes Metab. 2020 Aug;22(8):1388-1396. doi: 10.1111/dom.14046. Epub 2020 Apr 22. Diabetes Obes Metab. 2020. PMID: 32243036 Clinical Trial.
HDL as a Target for Glycemic Control.
Waldman B, Jenkins AJ, Sullivan D, Ng MKC, Keech AC. Waldman B, et al. Curr Drug Targets. 2017;18(6):651-673. doi: 10.2174/1389450116666150727115544. Curr Drug Targets. 2017. PMID: 26212264 Review.
133 results